On April 14, 2017, Abbott Laboratories agreed to acquire point-of-care diagnostics player Alere (ALR) for an equity value of ~$5.3 billion, ~$500 million lower than the price decided for Alere on January 31, 2016.
The existing terms of the agreement had to be amended after multiple regulatory and legal issues related to Alere were discovered following the original announcement of the acquisition.
In accordance with the new agreement, all regulatory approvals related to this transaction have to be secured by September 30, 2017.
